1 Unstoppable Dividend ETF Up 26% in 2026 to Buy and Hold for the Next 20 Years

The Schwab U.S. Dividend Equity ETF (SCHD) has delivered a 26% return year-to-date in 2026, significantly outperforming the S&P 500. The ETF focuses on 100 high-quality dividend-paying companies with at least 10 years of consecutive dividend payments, featuring a low 0.06% expense ratio and 3.3% dividend yield. Its portfolio emphasizes healthcare and consumer staples sectors, making it suitable for long-term buy-and-hold investors seeking stability and passive income.

07/31/2026, 10:18 AM • The Motley Fool

Prediction: This Dividend ETF Will Thrive After 20 Years No Matter What the Market Does

The Schwab U.S. Dividend Equity ETF (SCHD) is recommended as the best dividend ETF for long-term investors seeking a 20-year income strategy. Unlike the Vanguard Dividend Appreciation ETF (VIG) and iShares Core Dividend Growth ETF (DGRO), SCHD maintains better sector balance and prioritizes dividend yield and fundamental value, with top holdings in stable consumer staples like Coca-Cola, Merck, Chevron, and Procter & Gamble that will remain relevant over decades.

07/28/2026, 6:30 AM • The Motley Fool

After Soaring Nearly 90% Thus Far in 2026, Is Moderna's Stock Still a Buy?

Moderna's stock has surged nearly 90% in 2026, driven by positive FDA news about its flu vaccine mRNA-1010 in June. However, the rally appears unjustified as the vaccine is unlikely to generate significant revenue ($1B by 2028) and the company faces fundamental challenges including $3.4B in operating losses over the trailing 12 months, declining revenue, and dependence on COVID vaccine sales. With a $20B+ market cap and limited compelling growth catalysts beyond the experimental cancer vaccine mRNA-4157, the stock appears overvalued for its risk profile.

07/27/2026, 4:02 PM • The Motley Fool

Ascentage Pharma Chairman and CEO Dr. Dajun Yang Named to The Medicine Maker Power List 2026

Dr. Dajun Yang, Chairman and CEO of Ascentage Pharma, has been recognized in The Medicine Maker Power List 2026, ranking No. 3 in the Small Molecules category. The recognition highlights the company's achievements in advancing innovative cancer therapies, including the commercialization of olverembatinib and lisaftoclax, with multiple global Phase III clinical trials underway.

07/26/2026, 7:30 PM • GlobeNewswire

If I Were Starting My Portfolio From Scratch Today, This Is the First ETF I'd Buy

An experienced investor recommends the Schwab U.S. Dividend Equity ETF (SCHD) as the foundational holding for a new portfolio. The ETF focuses on high-yielding dividend-growth stocks and has delivered over 12% average annualized returns over multiple periods, outperforming pure growth stocks and high-yield stocks with lower volatility.

07/26/2026, 8:30 AM • The Motley Fool

2 Top Growth Stocks to Buy Right Now Without Any Hesitation

The article recommends Eli Lilly and Intuitive Surgical as outstanding healthcare stocks to buy. Eli Lilly is positioned as a leader in the rapidly growing weight management medicine market with approved drugs like Zepbound and Foundayo, plus promising pipeline candidates like retatrutide. Intuitive Surgical, despite recent underperformance and headwinds, is viewed as a buying opportunity due to the successful launch of its da Vinci 5 surgical system and strong long-term prospects driven by innovation and high switching costs.

07/24/2026, 12:30 AM • The Motley Fool

Which ETF Is Healthier for Your Portfolio: Vanguard Health Care ETF or iShares Pharmaceuticals ETF?

The article compares two healthcare-focused ETFs: Vanguard Health Care ETF (VHT) and iShares U.S. Pharmaceuticals ETF (IHE). VHT offers broader diversification with 411 holdings and a lower 0.09% expense ratio, while IHE provides concentrated pharmaceutical exposure with 56 holdings and has delivered superior 5-year returns (11.8% vs 5.4%). The author recommends IHE as the better buy for 2026 due to stronger recent performance and lower maximum drawdown, despite VHT's cost advantages.

07/22/2026, 4:33 PM • The Motley Fool

Want Income for Life? Here Are 3 Stocks to Buy Now and Never Sell.

The article recommends three dividend stocks suitable for long-term buy-and-hold investors: Pfizer, which is developing new blockbuster drugs and entering the obesity drug market; Coca-Cola, with 64 years of consecutive dividend increases and a resilient business model; and Brookfield Renewable, which offers recurring income from renewable energy assets with 5-9% annual dividend growth targets.

07/22/2026, 11:23 AM • The Motley Fool

Correction: Head and Neck Squamous Cell Carcinoma Market is Projected to Boost at a CAGR of 10.5% During the Forecast Period (2026–2036) Due to the Launch of Emerging Novel Immunotherapies | DelveInsight

The head and neck squamous cell carcinoma (HNSCC) market is expected to grow at a 10.5% CAGR from 2026-2036, driven by rising cancer incidence, increased adoption of immunotherapies, and the launch of emerging novel treatments. The market was valued at USD 850 million in 2025 across seven major markets, with KEYTRUDA currently generating the highest revenue among HNSCC therapies.

07/21/2026, 1:00 PM • GlobeNewswire

PD-1 and PD-L1 Inhibitors Clinical Trial Pipeline Analysis Demonstrates 180+ Key Companies on the Horizon Expected to Transform the Oncology Space | DelveInsight

A comprehensive analysis reveals over 180 companies developing 200+ PD-1 and PD-L1 inhibitor drugs across various clinical stages. The report highlights major pharmaceutical players advancing pipeline therapies for multiple cancer indications, with approximately 15+ drugs in late-stage development and 30+ in mid and early stages. Recent developments include FDA breakthrough designations and positive clinical trial results for combination therapies.

07/21/2026, 1:00 PM • GlobeNewswire

Autoimmune Disease Therapeutics Market Size to Reach USD 137.85 Billion by 2035 as Biologics and Precision Medicine Drive Growth | SNS Insider

The global autoimmune disease therapeutics market is projected to grow from USD 80.54 billion in 2025 to USD 137.85 billion by 2035, with a CAGR of 5.52%. Growth is driven by rising prevalence of autoimmune diseases, adoption of biologics, JAK inhibitors, monoclonal antibodies, and precision medicine technologies. North America leads with 39.96% market share, while Asia-Pacific shows the fastest growth at 6.28% CAGR.

07/15/2026, 11:00 AM • GlobeNewswire

Slate Medicines Strengthens Board of Directors with Appointment of Mark W. Hahn

Slate Medicines, a biotech company developing migraine treatments, announced the appointment of Mark W. Hahn to its Board of Directors. Hahn brings over 25 years of life sciences leadership experience, including serving as CFO at Verona Pharma during its $10 billion acquisition by Merck in 2025. His appointment comes as Slate advances SLTE-1009, a PACAP-targeting therapeutic for migraine prevention.

07/15/2026, 8:00 AM • GlobeNewswire

Oral Obesity Therapies Market to Reach $6.32 Billion by 2030 as Demand for GLP-1 Treatments Accelerates

The global oral obesity therapies market is projected to grow from $4.32 billion in 2026 to $6.32 billion by 2030, with a compound annual growth rate of 9.9%. The market expansion is driven by increasing demand for GLP-1 treatments, combination therapies, personalized metabolic treatments, and telehealth-enabled prescribing. Key opportunities include oral GLP-1 agonists, next-generation incretin drugs, and convenient non-injectable options for obesity management.

07/15/2026, 4:15 AM • GlobeNewswire

Head and Neck Squamous Cell Carcinoma Market is Projected to Boost at a CAGR of 10.5% During the Forecast Period (2026–2036) Due to the Launch of Emerging Novel Immunotherapies | DelveInsight

The head and neck squamous cell carcinoma (HNSCC) market is expected to grow at a CAGR of 10.5% from 2026-2036, driven by rising cancer incidence, increased adoption of immunotherapies, and the launch of emerging novel treatments. The market was valued at USD 850 million in 2025 across seven major markets, with KEYTRUDA currently generating the highest revenue. Multiple companies are advancing innovative therapies targeting HPV16-positive HNSCC and other molecular pathways.

07/13/2026, 1:00 PM • GlobeNewswire

Cosmos Health Accelerates Prescription Medicine Strategy with Libytec Partnership to Commercialize DIABIT-IS X in Greece

Cosmos Health has partnered with Libytec Pharmaceutical to commercialize DIABIT-IS X (sitagliptin), a generic diabetes medication, in Greece. Under a five-year agreement, Cosmos will supply the drug while Libytec handles distribution and promotion. As a prescription medicine covered by Greece's national health insurance system, DIABIT-IS X is positioned to reach a broad patient population and contribute meaningfully to revenue and cash flow.

07/13/2026, 1:00 PM • GlobeNewswire